Basic Furadantin Information

• INN (International Nonproprietary Name): Nitrofurantoin.
• Brand Names Available In Australia: Macrobid (listed as available in Australia); other global brands include Furadantin, Macrodantin, Furabid and Novo-Furan.
• ATC Code: J01XE01.
• Forms & Dosages: Capsules 25 mg, 50 mg, 100 mg, 100 mg ER; tablets 100 mg; oral suspension 25 mg/5 mL and 50 mg/5 mL for paediatric use.
• Manufacturers In Australia: not specified.
• Registration Status In Australia: not specified.
• OTC / Rx Classification: Prescription only (Rx).

Latest Research Highlights (Australian And International, 2022–2025)

Worried about rising antibiotic resistance and whether furadantin still works for a common UTI?

Recent Australian surveillance and international clinical reports from 2022–2025 continue to support nitrofurantoin as a key option for uncomplicated lower urinary tract infections where local susceptibility allows.

Community Escherichia coli isolates in many regions still frequently retain susceptibility to nitrofurantoin compared with some oral broad‑spectrum agents, according to surveillance summaries.

Reports note regional pockets of rising resistance and variable reporting between jurisdictions, so local antibiogram data remain crucial to choice of therapy.

Randomised trials and real‑world cohort analyses favour short‑course regimens for symptom relief and bacteriological cure in non‑pregnant adults, and extended‑release 100 mg formulations offer adherence advantages in practice.

Safety monitoring from 2022–2025 emphasises rare but serious pulmonary and hepatic reactions and peripheral neuropathy associated with prolonged use, consistent with the established pharmacovigilance profile of nitrofurantoin.

Australian submissions to regulators and hospital antibiograms emphasise stewardship: nitrofurantoin is recommended first‑line for uncomplicated cystitis but is not suitable for pyelonephritis or systemic urinary infections because of poor tissue penetration.

A concise, evidence‑focused approach is to check local resistance trends before prescribing and to reserve longer or suppressive courses for specialist review because of cumulative toxicity risk.

Clinical Effectiveness In Australia (Health Outcomes And TGA/PBS Context)

Are GPs and pharmacists in Australia still getting good results with furadantin for cystitis?

Nitrofurantoin is commonly prescribed in Australian primary care for uncomplicated cystitis and generally achieves good symptom resolution when local antibiograms indicate susceptibility.

PBS dispensing data and TGA adverse event reports position nitrofurantoin as a narrow‑spectrum, targeted option that supports antimicrobial stewardship compared with fluoroquinolones and other broad agents.

State health services tracking real‑world outcomes note lower re‑presentation rates when therapy is aligned with local susceptibility patterns.

TGA post‑market surveillance highlights rare but important harms, including pulmonary fibrosis and hepatotoxicity, mainly with long‑term or repeated use, and these reports inform PBS prescribing guidance and pharmacist counselling.

Telehealth prescribing has improved access, particularly in rural areas, but careful triage is required to exclude signs of complicated UTI before sending an e‑script for community dispensing.

Indications And Expanded Uses (TGA Approvals And Australian Off‑Label Practice)

Can furadantin be used for any UTI, or are there limits to when it should be given?

TGA‑aligned product information and common Australian practice position nitrofurantoin primarily for uncomplicated lower urinary tract infections (cystitis) in adults and selected paediatric patients aged one month and older.

Nitrofurantoin is not recommended for pyelonephritis, prostatitis or systemic infections because of poor tissue penetration compared with agents that achieve higher renal parenchyma and prostatic levels.

Off‑label uses in Australia include low‑dose nightly prophylaxis for recurrent uncomplicated UTI and selective use in older women when alternatives are unsuitable, but these strategies require specialist input because of cumulative toxicity risk.

Pregnancy guidance from product information advises avoidance from 38 weeks’ gestation and during labour because of neonatal haemolysis risk, and the drug is contraindicated in infants under one month of age.

• Approved (TGA): Uncomplicated cystitis in adults and selected paediatric patients.
• Off‑label / Caution: Low‑dose prophylaxis for recurrent UTI, selective older patient use; escalate to specialist review for longer‑term therapy.

Composition And Brand Landscape (Active Ingredients, Brands, Packaging)

Which brands and formulations of nitrofurantoin might you see on a shelf or in a prescription?

The active ingredient is nitrofurantoin (INN), ATC code J01XE01.

Major global brands include Furadantin, Macrodantin, Macrobid, Furabid and Novo‑Furan, with Macrobid listed as available in Australia.

Commercial formulations sold worldwide include capsules (25 mg, 50 mg, 100 mg), a 100 mg extended‑release capsule, tablets and oral suspensions (25–50 mg/5 mL) for paediatric dosing.

Packaging is typically blister packs or bottles in counts around 30, 50 or 100 units, with suspensions commonly in 100 mL bottles.

• Available Strengths: 25 mg, 50 mg, 100 mg, 100 mg ER; oral suspensions 25 mg/5 mL and 50 mg/5 mL.

Contraindications And Special Precautions (High‑Risk Groups And Daily‑Life Restrictions)

Who should not take furadantin, and what should pharmacists check before supply?

Absolute contraindications include severe renal impairment (CrCl or eGFR <30 mL/min), known allergy to nitrofurantoin, prior nitrofurantoin‑related jaundice or hepatic dysfunction, pregnancy from 38 weeks’ gestation to delivery, and infants under one month.

Relative cautions include G6PD deficiency because of haemolysis risk, elderly patients who are at higher risk of pulmonary reactions and peripheral neuropathy, and people with vitamin B deficiency or pre‑existing peripheral neuropathy.

Practical daily‑life advice is to take nitrofurantoin with food to reduce nausea, expect brown urine which is harmless, avoid heavy machinery or driving if dizzy or drowsy, and notify occupational health if new neurological symptoms appear.

For Indigenous and remote patients, pre‑treatment renal function screening and consideration of G6PD status where relevant are culturally and clinically important steps prior to starting therapy.

Dosage Guidelines (Standard Regimens And Adjustments)

What is the usual nitrofurantoin dose for a simple bladder infection, and how is dosing changed for children or kidney disease?

Standard adult dosing for acute uncomplicated cystitis is 50–100 mg every six hours (four times daily) for seven days.

Prophylactic dosing for recurrent infections is commonly 50–100 mg at bedtime using the lowest effective dose.

Paediatric dosing for infants aged one month and older is typically 5–7 mg/kg/day divided into four doses, with suspension strengths of 25 mg/5 mL or 50 mg/5 mL used for calculations.

Nitrofurantoin is contraindicated in severe renal impairment (CrCl <30 mL/min) and should be avoided or used with caution in moderate impairment; renal function should be monitored in elderly patients.

Treatment duration is usually at least seven days or continued for three days after bacteriological clearance in recurrent cases, with clinical judgement guiding duration.

If a dose is missed, take it as soon as remembered unless it is near the time of the next dose; do not double up doses.

In overdose, provide symptomatic and supportive care and seek urgent medical assistance; severe nausea and vomiting are commonly reported overdose symptoms.

Interactions Overview (Food, Drugs, Urine PH And Clinical Systems)

Will anything you eat or other medicines you take make furadantin less effective or more risky?

Nitrofurantoin activity decreases in alkaline urine, so alkalising agents such as potassium citrate may reduce its efficacy.

Drugs that impair renal function or reduce renal clearance can increase systemic exposure to nitrofurantoin and heighten toxicity risk, so review concomitant medicines that affect eGFR.

There are no prominent CYP‑mediated metabolic interactions, but co‑prescription with other neurotoxic drugs increases the risk of peripheral neuropathy.

Alcohol does not directly alter nitrofurantoin pharmacokinetics but can worsen side effects such as nausea and dizziness, so moderation is recommended while taking the drug.

TGA and e‑health interaction tools flag the most important interactions as clinical (renal function and additive neurotoxicity) rather than classic metabolic drug–drug interactions.

Cultural Perceptions And Patient Habits (Australian Patient Behaviour, Rural Versus Urban)

How do Australians typically find and take nitrofurantoin, and are there access differences between city and country patients?

Australian patients commonly rely on pharmacists and major pharmacy chains for price comparisons and advice, and PBS availability influences adherence and brand choice.

Rural and remote communities often use telehealth and local pharmacies to access prescriptions, which can lead to delays or substitutions if certain strengths or ER formulations are not stocked locally.

Patient forums and social media frequently raise questions about long‑term lung and nerve side effects, breastfeeding safety, and pregnancy‑related concerns.

Cultural competence in counselling includes respectful discussion with Indigenous patients about kidney health and medication risks, checking renal function before initiation, and considering travel logistics for dosing schedules during remote travel.

• Rural Vs Urban Access: Telehealth increases access in remote areas but local stock limits may require early pharmacy notification.
• Patient Concerns: Side effects and pregnancy‑breastfeeding queries are commonly raised and should be addressed with product information and TGA guidance.

Availability And Pricing Patterns (Major Pharmacies, Online/Telehealth And PBS)

Where can you get furadantin in Australia and how much might it cost?

Nitrofurantoin is prescription‑only and dispensed through community pharmacies including major chains such as Chemist Warehouse, Priceline and TerryWhite Chemmart, and through online pharmacies accepting e‑prescriptions from telehealth services.

PBS subsidisation commonly applies for appropriately indicated uncomplicated UTIs, so check current PBS listings and patient eligibility for concessional pricing.

Private prices vary across pharmacies and between branded and generic products, with consumers often comparing chain specials and generics to reduce cost.

Rural pharmacies may have limited stock of 100 mg ER formulations or paediatric suspensions, so prescribers and pharmacists should communicate early to ensure supply.

In our online pharmacy, furadantin is available without a prescription, with discreet delivery to Australia in 5–14 days.

Comparable Medicines And Preferences (Alternatives, Pros And Cons)

When might a clinician prefer another antibiotic to furadantin for a UTI?

Common oral alternatives in Australia for uncomplicated cystitis include fosfomycin (where available), trimethoprim, co‑trimoxazole (sulfamethoxazole‑trimethoprim) and, in selected cases, ciprofloxacin which is usually reserved.

Advantages of nitrofurantoin include its narrow spectrum, retained activity against many community Escherichia coli strains and relatively low collateral damage to gut flora.

Limitations include unsuitability for upper urinary tract infection or systemic infection, restriction in renal impairment and cumulative toxicity risk with prolonged use.

Fosfomycin offers single‑dose convenience where it is locally available, while trimethoprim is often cheaper but its utility is reduced in areas with rising resistance.

Clinicians weigh local susceptibility, pregnancy status, renal function and PBS access or cost when choosing between nitrofurantoin and alternatives.

• When To Choose Nitrofurantoin: Uncomplicated cystitis with confirmed or likely susceptible organisms and adequate renal function.
• When To Consider Alternatives: Suspected pyelonephritis, systemic infection, eGFR <30 mL/min, or documented resistance to nitrofurantoin.

FAQ

Is Furadantin available over the counter?

No—nitrofurantoin (Furadantin/Macrobid) is prescription‑only in Australia; see a GP or use a telehealth service for an e‑script.

Is nitrofurantoin on the PBS?

It is often subsidised for appropriately indicated uncomplicated UTIs; confirm current PBS listings and patient eligibility before dispensing.

Can I drink alcohol while taking nitrofurantoin?

Alcohol does not reduce efficacy but may worsen side effects such as nausea or dizziness, so moderation is advised while taking the medicine.

Is nitrofurantoin safe in pregnancy or breastfeeding?

Avoid nitrofurantoin from 38 weeks’ gestation and during labour because of neonatal haemolysis risk, and do not use in infants under one month; use earlier in pregnancy only when benefits outweigh risks and after discussion with the treating clinician.

When Should I Call My GP?

Contact your GP or go to emergency care if you have fever, flank pain, worsening symptoms, shortness of breath, persistent cough, jaundice, or new numbness or weakness while taking nitrofurantoin.

Guidelines For Proper Use (Pharmacist Counselling And Patient Advice)

What should pharmacists check and tell patients when dispensing furadantin?

Confirm the indication is uncomplicated cystitis and check recent renal function (eGFR/CrCl), pregnancy status and patient age to rule out infants under one month or late pregnancy.

Review concurrent medications for renal risk or additive neurotoxicity and ask about G6PD deficiency before supply for those at risk of haemolysis.

Advise patients to take nitrofurantoin with food to reduce gastrointestinal upset and to expect harmless brown urine as a side effect.

Instruct patients to complete the full prescribed course, to report breathlessness, persistent cough, jaundice or new numbness immediately, and to avoid doubling doses if a dose is missed.

For telehealth prescriptions, confirm local pharmacy stock and PBS eligibility prior to dispensing to avoid delays, especially for ER formulations or paediatric suspension.

Document adverse drug reactions and report them to the TGA, and escalate any prolonged or repeated therapy to specialist review because of cumulative pulmonary and neuropathy risks.

• Pharmacist Checklist: Confirm indication, check renal function, confirm pregnancy/breastfeeding status, review drug interactions, provide counselling on side effects and ADR reporting.
• Patient Leaflet Points: Take with food, expect brown urine, finish course, call GP for breathing problems, cough or jaundice.

Delivery Across Australia